Guidance
Skip Standards and indicators submenu
Quality standards
Our quality standards set out priority areas for quality improvement. They highlight areas with identified variation in current practice.
View our quality standards
How to use our quality standards
The timeline for developing quality standards
Help us develop quality standards
Selecting and prioritising quality standards topics
About quality standards
Indicators
Our indicators measure outcomes that reflect the quality of care, or processes linked by evidence to improved outcomes.
View list of indicators
Learn about the committee that develops indicators
About indicators
Skip Life sciences submenu
Life Sciences
We offer tailored support to industry during product development. Our expertise can help you build the evidence needed to achieve market access.
View life sciences
Get support from NICE
NICE Advice service
Trusted, unrivalled expertise.
Make an enquiry
Contact us to discuss your requirements.
Innovative Licensing and Access Pathway (ILAP)
Streamlining patient access to safe, financially sustainable and innovative medicines.
Learn how we evaluate technologies
Health technology evaluation and topic selection manuals
Updated manuals for methods, processes and topic selection.
Digital health technologies
Accelerating our efforts to deliver innovation to the health and care system.
Evidence standards framework
Using the best available evidence to develop recommendations that guide decisions in health, public health and social care.
Our guidance programmes
Ensuring new technologies are clinically effective and offer economic value.
Register your product
Non-pharmaceutical
NHS Innovation Service is a clear and simple point of entry for health technologies to access support and national evaluation programmes.
Pharmaceutical
UK PharmaScan is a database of new medicines, indications and formulations in the pharmaceutical pipeline.
Find published and proposed evaluations
Diagnostics
Guidance on measurements and tests used to evaluate a patient's condition.
Medical technologies
Guidance on medical technologies put forward to NICE by manufacturers.
Technology appraisals
Guidance on new and existing medicines and treatments in the NHS.
Highly specialised technologies
Guidance on the use of highly specialised medicines and treatments.
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
Skip About submenu
About
NICE helps practitioners and commissioners get the best care to patients, fast, while ensuring value for the taxpayer.
Explore about
Our programmes
Learn about the information we produce.
Guidance
Advice
Quality standards
Indicators
Digital health
Topic selection
Get involved
Understand how decisions are made:
Attend a committee meeting
Comment on draft guidance:
Guidance in consultation
Be part of a guidance committee:
Join a committee
Help develop our products:
Register as a stakeholder
Putting you at the heart of our work:
Public involvement
What we do
Social care
Life sciences
NICE international
Patient safety
Shared decision making
Into practice
Social care quick guides
Measuring the use of NICE guidance
Resource planner
View all Into practice
Who we are
The board
The NICE strategy 2021 to 2026
Corporate publications
View all Who we are
- Contact us
- Jobs

Brain tumours (primary) and brain metastases in over 16s

NICE guideline
Reference number: NG99
Published: 11 July 2018
Last updated: 29 January 2021

History

Expected publication

Consultation comments and responses (PDF 1.3 MB)

Published:

11 July 2018
Equality impact assessment (PDF 137 KB)

Published:

11 July 2018
Committee member list (PDF 948 KB)

Published:

11 July 2018

Equality and health inequalities assessment

Equality impact assessment (PDF 137 KB)

Published:

19 April 2018

Draft guidance consultation

Draft guidance consultation
Evidence review A (PDF 7.77 MB)

Published:

12 January 2018
Evidence review D (PDF 1.67 MB)

Published:

12 January 2018
Addendum appendix 1 (PDF 389 KB)

Published:

12 January 2018
Addendum appendix 2 (PDF 536 KB)

Published:

12 January 2018
Addendum appendix 3 (PDF 883 KB)

Published:

12 January 2018
Addendum appendix 4 (PDF 5.72 MB)

Published:

12 January 2018
Draft guideline (PDF 688 KB)

Published:

12 January 2018
Comments form (MSWord 63 KB)

Published:

12 January 2018
Evidence review B (PDF 4.15 MB)

Published:

12 January 2018
Evidence review C (PDF 7.24 MB)

Published:

12 January 2018
Equality impact assessment (PDF 271 KB)

Published:

18 January 2018

Pre-consultation documents released

Economic plan (PDF 173 KB)

Published:

23 November 2017
Review questions (PDF 218 KB)

Published:

23 November 2017
Search strategies (PDF 5.67 MB)

Published:

23 November 2017

Committee meetings

Committee meeting
Minutes - meeting 1 (PDF 286 KB)

Published:

26 July 2016
Minutes - meeting 2 (PDF 207 KB)

Published:

20 September 2016
Minutes - meeting 3 (PDF 290 KB)

Published:

17 November 2016
Minutes - meeting 4 (PDF 276 KB)

Published:

25 January 2016
Minutes - meeting 5 (PDF 267 KB)

Published:

09 March 2017
Minutes 6 (PDF 267 KB)

Published:

10 November 2017
Minutes 7 (PDF 335 KB)

Published:

10 November 2017
Minutes 8 (PDF 214 KB)

Published:

10 November 2017
Minutes 9 (PDF 320 KB)

Published:

10 November 2017
Minutes 10 (PDF 320 KB)

Published:

08 March 2018

Stakeholder list updated

Stakeholder list (PDF 43 KB)

Published:

10 January 2018

Scope published

Consultation comments and responses (PDF 590 KB)

Published:

19 August 2016
Equality impact assessment 2 (PDF 134 KB)

Published:

19 August 2016
Final scope (PDF 257 KB)

Published:

19 August 2016

Committee list updated

Committee member list (PDF 93 KB)

Published:

19 August 2016

Draft scope consultation

Draft scope consultation
Draft scope (PDF 212 KB)

Published:

17 May 2016
Equality impact assessment 1 (PDF 118 KB)

Published:

18 May 2016

Scoping workshop

Workshop notes (PDF 227 KB)

Published:

17 May 2016
Minutes - Meeting 6 (PDF 267 KB)

Published:

19 June 2017